shirley gordon, pb, pwc board member, and leah mimoun, our intern and former pb, pwc scholarship recipient. thank you both for coming on the show. >> thank you. we appreciate you. thank you. >> remember, abc seven news is streaming 24 seven. you can get the abc7 bay area app and join us whenever you want, wherever it's from around the bay area. world news tonight with >>> tonight, breaking news. president biden's surprise debate challenge to donald trump. tonight, donald trump saying yes. both agreeing to two presidential debates. one right here on abc. also tonight, the chilling images, the attempted assassination overseas. >>> and here at home, we're tracking severe storms on the move right now. >>> first tonight, the debate showdown between president biden and donald trump. president biden issuing that challenge, former president trump accepting. the first debate before the conventions on cnn.

cnbc contributor and sits on a number of boards within the healthcare space good morning good to see you. >> good morning, frank >> i was just looking at data from pwcn pharma, you have the potential to boost profits $254 billion a year globally by 2030 when you talk about this, what areas in pharma and drug development do you see benefitting the most and the most in the near term? >> frank, pharma is a very intelligent industry intelligent a.i. is here and it is making a big, big impact industry after industry, especially in the industry like pharma in pharma, the biggest opportunity is for new drugs that's content creation. new content creation a.i. can go through vast data sets and help you get to much better drug molecules in a more efficient man aftner and come u with new molecules than ever before huge opportunities there there is a huge opportunity with clinical trials and finding the right patients and finding the right sites and finding the right way to get through clinical trials and enormous opportunities to manage patients a lot better for doctors pharma is going to benefit from it >> i really want to lean into your insights. it is some

board has consolidated power under sam altman, and the drive to commercialize his only gaming momentum, which could complicate openai openai's relationship with its biggest backer, microsoft. enterprise is microsoft's bread and butter. pwce those licenses going to microsoft in another kind of land scape. so guys, i wanted to end on this chart here. i thought it was interesting. it's microsoft versus google. since last november when the openai drama broke out, microsoft has been slow to monttize it's co-pilot, raising the question of this pwc deal. would openai represent more competition ahead and are some of those reputational risks having an impact on microsoft? because it is openai's biggest backer. >> that chart is great, deidre, because in that moment, if you rewind the clock, we would have thought microsoft is going to well outperform google and they trailed them. google has done twice as well. do we know more about -- i wish that i could get more tangible, you know, visuals of what it's like using the openai product versus co-pilot. this is what this is all now going to come down to, isn't it? >> it is. i think maybe different use cases. in the deal with pwc, pwc is using chatgbt to create they ca pwc. and they wi